Banca de DEFESA: ANDREIA DIAS TEIXEIRA

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : ANDREIA DIAS TEIXEIRA
DATE: 21/06/2022
TIME: 09:00
LOCAL: https://conferenciaweb.rnp.br/events/defesa-de-dissertacao-da-mestranda-andreia-dias-teixeira.
TITLE:

ESTIMATED FINANCIAL SAVINGS WITH PHARMACEUTICAL CARE OFFER: AN ASSESSMENT BASED ON A THEORETICAL MODEL

KEY WORDS:

Drug-related morbidity; economic impact; health economics; panel with experts; therapeutic failure; problems related to pharmacotherapy; drug related problems; pharmaceutical care

PAGES: 61
BIG AREA: Ciências da Saúde
AREA: Farmácia
SUMMARY:

Objective: To estimate, through a theoretical model, the occurrence of new drug prescriptions due to failure in the previous treatment, estimating the monetary costs of these new prescriptions, and to demonstrate, from the result, the importance of offering Pharmaceutical Care. Method: This is an analytical, transversal and quantitative intervention study, with semi-structured interviews, carried out with a panel of pharmacists and doctors, linked to the Unified Health System, in a municipality of 295,000 inhabitants, who estimated, through the use of of a theoretical model of probability pathway the occurrence of a new medical prescription due to therapeutic failure in a previous prescription, where there was no Pharmaceutical Care. Then, according to the average obtained by the expert panel, the final costs were obtained by adding the conditionals: the cost of a new prescription was added to the cost of a new medical consultation, also added to the previous prescription that caused the treatment failure, and the respective medical consultation that gave rise to this prescription. In the end, the cost result obtained was reduced by 10% to reflect the rate of new prescriptions never filled, even when treatment fails. Results: As estimated by the expert panel, 41.73±19.34 patients out of every 100 outpatients who do not receive Pharmaceutical Care experience therapeutic failure. The associated costs were entered, resulting in an expense of BRL R$8.823.260,16±1.706.418,51. Then, when decreasing by 10%, we arrive at an estimated cost of R$ R$7.940.934,14±1.535.776,66, with the occurrence of a new prescription due to failure in previous treatment in 2019, in the SUS outpatient services of the municipality in the year 2019. Conclusion: It is concluded that the offer of Pharmaceutical Care, with the availability of pharmaceutical services in outpatient clinics in the SUS, does not represent an increase in expenses, but an economy to the public coffers. Pharmaceutical Care should be used as a priority tool for public policies on access to medication, thus being able to reduce drug-related morbidity and mortality and consequently the financial cost in health.

BANKING MEMBERS:
Presidente - 285863 - JUCENI PEREIRA DE LIMA DAVID
Interno - 2765101 - ADEMIR EVANGELISTA DO VALE
Interno - 2556460 - PABLO DE MOURA SANTOS
Externo à Instituição - DIOGO PILGER - UFRGS